| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
Antidepressant agent 10 functions as a dual-target 5-HT receptor modulator. Its primary molecular targets are the serotonin receptors 5-HT1A and 5-HT2. It acts as an inhibitor at these receptors, making it a valuable tool for understanding the role of serotonin signaling in mood regulation and psychiatric diseases. The compound is not a drug itself but is used in preclinical research to explore new antidepressant mechanisms.
|
|---|---|
| ln Vitro |
In vitro, Antidepressant agent 10 demonstrates potent and selective inhibitory activity against serotonin receptors. It exhibits IC50 values of 190 nM for the 5-HT1A receptor and 110 nM for the 5-HT2 receptor. This potent dual inhibition of key serotonin receptor subtypes is the basis for its classification as an antidepressant agent and makes it a useful pharmacological tool for studying serotonin-related signaling pathways in cell-based systems.
|
| ln Vivo |
In vivo, Antidepressant agent 10 is described as an orally active compound, indicating it is absorbed and can exert systemic effects when administered to animals by mouth. It is used in the research of mental disorders, including depression and anxiety, in preclinical animal models. Its activity in vivo is presumed to be mediated through its antagonism of 5-HT1A and 5-HT2 receptors in the central nervous system, leading to alterations in serotonergic neurotransmission and subsequent behavioral changes relevant to mood and cognition.
|
| Enzyme Assay |
Non-cellular (cell-free) experiments for Antidepressant agent 10 typically involve radioligand binding assays to determine its affinity and IC50 values at serotonin receptors. A standard protocol involves incubating the compound with membrane preparations from cells expressing human recombinant 5-HT1A or 5-HT2 receptors and a specific radiolabeled ligand (e.g., [3H]-8-OH-DPAT for 5-HT1A). After incubation, the mixture is filtered to separate bound from free radioligand, and the radioactivity on the filters is measured using a scintillation counter to calculate percent inhibition and IC50.
|
| Cell Assay |
Cell-based experiments for Antidepressant agent 10 involve functional assays to measure serotonin receptor activity. For 5-HT2A functional antagonism, cells (e.g., HEK-293 cells stably expressing the 5-HT2A receptor) are loaded with a calcium-sensitive fluorescent dye. The compound is pre-incubated, and then the receptor is challenged with a 5-HT agonist. Intracellular calcium flux is measured using a fluorescence plate reader; a decrease in fluorescence indicates antagonism. For 5-HT1A, a GTPgammaS binding assay is used in CHO cells expressing the receptor, measuring agonist-stimulated [3⁵S]GTPgammaS binding which is inversely correlated with antagonist activity.
|
| Animal Protocol |
In vivo animal experiments for Antidepressant agent 10 are conducted in rodent models of depression. A typical protocol involves oral administration of the compound to rats or mice at varying doses (e.g., 1-30 mg/kg). After a defined time (e.g., 30-60 minutes), animals are subjected to a behavioral test such as the Forced Swim Test (FST) or the Tail Suspension Test (TST). The duration of immobility is recorded; a significant reduction in immobility time compared to vehicle-treated controls indicates an antidepressant-like effect. Open field tests are performed simultaneously to rule out false positives due to general locomotor effects.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) data for Antidepressant agent 10 is limited in public literature. It is, however, characterized as an "orally active" compound, which implies it is absorbed from the gastrointestinal tract. As a small, moderately lipophilic molecule, it is predicted to have moderate to high oral bioavailability and to cross the blood-brain barrier. It is an intermediate in Ziprasidone synthesis, so it may share some metabolic pathways. For storage, it is stable at room temperature, protected from light, and can be stored in solvent at -80degC for up to 2 years or at -20degC for 1 year.
|
| Toxicity/Toxicokinetics |
Detailed toxicological data for Antidepressant agent 10 is not publicly available. As with any research chemical, standard safety precautions should be taken. It should be treated as potentially harmful if ingested, inhaled, or absorbed through the skin. It may cause skin and eye irritation. The compound is a controlled substance in certain territories, and is not for sale to patients. All handling should be performed in a well-ventilated area, such as a chemical fume hood, while wearing appropriate personal protective equipment.
|
| References | |
| Additional Infomation |
Other information: Antidepressant agent 10 is a solid at room temperature with a molecular weight of 219.31 g/mol. Its IUPAC name is 3-piperazin-1-yl-1,2-benzothiazole, and its SMILES code is C1(N2CCNCC2)=NSC3=C1C=CC=C3. The compound is a fragment molecule suitable as a scaffold for medicinal chemistry campaigns. It is used in the research of mental disorders and is referenced in the synthesis of tiospirone metabolites. It is for research use only and not intended for human or veterinary applications.
|
| Molecular Formula |
C11H13N3S
|
|---|---|
| Molecular Weight |
219.31
|
| Exact Mass |
219.083
|
| CAS # |
87691-87-0
|
| PubChem CID |
2772144
|
| Appearance |
Typically exists as solids at room temperature
|
| Hydrogen Bond Donor Count |
1
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
15
|
| Complexity |
218
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CN(CCN1)C2=NSC3=CC=CC=C32
|
| InChi Key |
KRDOFMHJLWKXIU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H13N3S/c1-2-4-10-9(3-1)11(13-15-10)14-7-5-12-6-8-14/h1-4,12H,5-8H2
|
| Chemical Name |
3-piperazin-1-yl-1,2-benzothiazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5598 mL | 22.7988 mL | 45.5976 mL | |
| 5 mM | 0.9120 mL | 4.5598 mL | 9.1195 mL | |
| 10 mM | 0.4560 mL | 2.2799 mL | 4.5598 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
